𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Kinetics of citalopram in elderly patients

✍ Scribed by K. Fredericson Overø; B. Toft; L. Christophersen; J. P. Gylding-Sabroe

Publisher
Springer
Year
1985
Tongue
English
Weight
518 KB
Volume
86
Category
Article
ISSN
0033-3158

No coin nor oath required. For personal study only.

✦ Synopsis

The kinetics of the antidepressant drug citalopram, a specific 5-HT uptake inhibitor, has been investigated in 11 elderly patients (age 73-90) and compared to previous data from younger patients and volunteers. The recorded steady state citalopram levels of 140-545 nM after a once-daily 20-mg dose were up to four times higher than expected from data in younger patients and volunteers. The biological half-life (1.5-3.75 days) and estimated systemic clearance (0.08-0.3 1/min) also differed from data in younger individuals (1.5 days and 0.4 1/min, respectively). Clearance values generally decreased with increasing age. Drug/metabolite ratios were higher in patients with the longest half-lives and lowest citalopram clearance, indicating reduced metabolic activity. No reduction in renal clearance was indicated by urine data, obtained for two of the patients. The study suggests that daily doses of 5-20 mg give approximately the same steady state plasma levels in elderly patients as doses of 40 mg in younger, and that this is due to reduced rates of metabolism in the elderly.

📜 SIMILAR VOLUMES

Citalopram-lithium combination treatment
Citalopram-lithium combination treatment of elderly depressed patients: A pilot study
✍ Claude Uehlinger; Rico Nil; Marlyse Amey; Dr Pierre Baumann; Henri Dufour 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 472 KB

Fourteen elderly depressive patients (age 67-88 yr), phenotyped with dextromethorphan and rnephenytoin before and during the trial, were treated for 4 weeks with citalopram (final dose 20-30 mg/day, except one patient 60 mg/day). The clinical state of the patients was recorded weekly using the Hamil

Comparison of the tolerability and effic
Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice
✍ C. J. Kyle; Hans Erik Høpfner Petersen; Kerstin Fredricson Overø 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB 👁 2 views

The enhanced sensitivity of the elderly to the side effects produced by tricyclic antidepressants (TCAs), and the frequency and type of adverse events, have made the treatment of depression in this group difficult. The selective serotonin reuptake inhibitors (SSRIs) have been reported to produce sig

Citalopram augmentation of antipsychotic
Citalopram augmentation of antipsychotic treatment in older schizophrenia patients
✍ John W. Kasckow; Somaia Mohamed; Arthur Thallasinos; Brendan Carroll; Sidney Zis 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 54 KB

## Abstract ## Background Depressive symptoms are common in older patients with schizophrenia; yet, few studies have examined the usefulness of antidepressants in this population. ## Objective We conducted a 10‐week single‐blind trial of citalopram (20–40 mg/day) vs no citalopram augmentation in